ArticleImmunity2021
The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 114 citations in OpenAlex.
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- Integrative multi-omics analysis and machine learning identify M2 macrophage-induced ferroptosis resistance in glioblastoma.Functional & integrative genomics · 2026Article
- Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.Cellular & molecular immunology · 2026Article
- Signal peptide peptidase- and SPP-like 3-dependent shedding of α1,6-fucosyltransferase differentially affects core fucosylation.The Journal of biological chemistry · 2026Article
- Designing universal T cell therapies: strategies to evade natural killer cells.Frontiers in immunology · 2026Review
- ZEB1, a novel junctional adhesion molecule A regulator, impacts sensitivity of pancreatic cancer-associated fibroblasts to reovirus.Molecular therapy. Oncology · 2025Article
- HLA-A drives diabetic retinopathy pathogenesis: multi-omics integration reveals resveratrol's therapeutic potential via immunomodulation.Journal of translational medicine · 2025Article
- UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion.Signal transduction and targeted therapy · 2025Article
- Unraveling the glyco-immunity nexus in pancreatic cancer.Molecular cancer · 2025Review
- Metabolomic profiling reveals interindividual metabolic variability and its association with cardiovascular-kidney-metabolic syndrome risk.Cardiovascular diabetology · 2025Article
- Linking Lipid Metabolism and Immune Function: New Insights into Chronic Respiratory Diseases.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Review
- Machine learning-driven prognostic model based on sphingolipid-related gene signature in pancreatic cancer: development and validation.Translational cancer research · 2025Article
- Glycosphingolipids as emerging attack points in bladder cancer.Discover oncology · 2025Review
- The genetic overlap between major depressive disorder, white blood cell counts and interleukin 6.Journal of affective disorders reports · 2025Article
- Integrated bioinformatics and clinical data identify three novel biomarkers for osteoarthritis diagnosis and synovial immune.Scientific reports · 2025Article
- Massively parallel interrogation of human functional variants modulating cancer immunosurveillance.Signal transduction and targeted therapy · 2025Article
- Tumor-Expressed SPPL3 Supports Innate Antitumor Immune Responses.European journal of immunology · 2025Article
- Genetic Risk Profiling Reveals Altered Glycosyltransferase Expression as a Predictor for Patient Outcome in Neuroblastoma.Journal of clinical medicine · 2025Article
- Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma.Scientific reports · 2025Article
- Synthesis, function, and therapeutic potential of glycosphingolipids.Frontiers in immunology · 2025Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
28 authors at 11 institutions in 4 countries.
Marlieke L M JongsmaDepartment of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands; Oncode Institute and Department of Cell and Chemical Biology, LUMC, Leiden, the Netherlands.
Antonius A de WaardDepartment of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Matthijs RaabenOncode Institute, Division of Biochemistry, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Tao ZhangCenter for Proteomics and Metabolics, LUMC, Leiden, the Netherlands.
Birol CabukustaOncode Institute and Department of Cell and Chemical Biology, LUMC, Leiden, the Netherlands.
René PlatzerInstitut für Hygiene und Angewandte Immunologie, Vienna, Austria.
Vincent A BlomenOncode Institute, Division of Biochemistry, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Anastasia XagaraDepartment of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Tamara VerkerkDepartment of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Sophie BlissDepartment of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Xiangrui KongDepartment of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Carolin GerkeInstitute of Virology, Medical Center University of Freiburg, Freiburg, Germany; Faculty of Medicine, University of Freiburg, Freiburg, Germany; Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany.
Lennert JanssenOncode Institute and Department of Cell and Chemical Biology, LUMC, Leiden, the Netherlands.
Elmer StickelOncode Institute, Division of Biochemistry, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Stephanie HolstCenter for Proteomics and Metabolics, LUMC, Leiden, the Netherlands.
Rosina PlompCenter for Proteomics and Metabolics, LUMC, Leiden, the Netherlands.
Arend MulderDepartment of Immunology, LUMC, Leiden, the Netherlands.
Soldano FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Frans H J ClaasDepartment of Immunology, LUMC, Leiden, the Netherlands.
Mirjam H M HeemskerkDepartment of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
Marieke GriffioenDepartment of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
Anne HaleniusInstitute of Virology, Medical Center University of Freiburg, Freiburg, Germany; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Hermen OverkleeftLeiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.
Johannes B HuppaInstitut für Hygiene und Angewandte Immunologie, Vienna, Austria.
Manfred WuhrerCenter for Proteomics and Metabolics, LUMC, Leiden, the Netherlands.
Thijn R BrummelkampOncode Institute, Division of Biochemistry, the Netherlands Cancer Institute, Amsterdam, the Netherlands; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Cancer Genomics Center, Amsterdam, the Netherlands.
Jacques NeefjesOncode Institute and Department of Cell and Chemical Biology, LUMC, Leiden, the Netherlands.
Robbert M SpaapenDepartment of Immunopathology, Sanquin Research, Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address: r.spaapen@sanquin.nl.
Leiden University Medical Center · NLNetherlands Metabolomics Centre · NLOncode Institute · NLCancer Center AmsterdamThe Netherlands Cancer Institute · NLUniversity Medical Center Freiburg · DEUniversity of Amsterdam · NLAmsterdam University Medical Centers · NLHarvard University · USLeiden University · NLSanquin · NL
Funding
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancerR01DE028172 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XINHUI · 2018 to 2022
$1.9MIL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinomaR03CA231766 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FERRONE, CRISTINA R., FERRONE, SOLDANO · 2018 to 2019
$177kIL-15 TRiKES-based specific immunotherapy of TNBC; resistance mechanismsR03CA216114 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FERRONE, SOLDANO, VALLERA, DANIEL A · 2018 to 2019
$177kSafety and anti-tumor activity of B7-H3 CAR T cells in TNBCR03CA223886 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DOTTI, GIANPIETRO, FERRONE, SOLDANO · 2018 to 2019
$176kNCI NIH HHS R03 CA216114NCI NIH HHS R03 CA223886NCI NIH HHS R03 CA231766NIDCR NIH HHS R01 DE028172
Abstract
HLA class I (HLA-I) glycoproteins drive immune responses by presenting antigens to cognate CD8
Indexed as
Antigen PresentationAspartic Acid EndopeptidasesCD8-Positive T-LymphocytesCell Line, TumorGene Expression Regulation, NeoplasticGene Knockdown TechniquesGliomaGlycosphingolipidsGlycosyltransferasesHistocompatibility Antigens Class IHLA AntigensHumansImmunotherapyLymphocyte ActivationSignal TransductionSurvival AnalysisAspartic Acid EndopeptidasesB3GNT5 protein, humanGlycosphingolipidsGlycosyltransferasesHistocompatibility Antigens Class IHLA Antigenssignal peptide peptidase like 3, humanantigen presentationB3GNT5gliomaglycosphingolipidsHLA class Iimmune recognitionimmunotherapyMHC class ISPPL3T cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.